Former J&J senior exec joins board of Advanced Cardiac Therapeutics
This article was originally published in Clinica
Roy Tanaka, former president of Johnson & Johnson's Biosense Webster division, has been elected to the board of directors at cardiac ablation system developer Advanced Cardiac Therapeutics (ACT). Mr Tanaka joined Biosense Webster, which specialises in technologies for treating cardiac arrhythmias, as US president in 1997. He then served as worldwide president from 2004-2008. He has also held senior management roles at Sorin Biomedical, CooperVision Surgical and Pfizer-subsidiary Shiley. Laguna Beach, California-based ACT has developed the TEMPASURE cardiac ablation catheter for treating atrial fibrillation. It is said to be the world’s first temperature-sensing cardiac ablation catheter; the technology was first developed to spy on Soviet crop growth. ACT raised $5m in series B financing earlier this year and initiated its first-in-man trial in March.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.